A recent large-scale randomized controlled trial (RCT) demonstrated that rectal indomethacin administration is effective in addition to pancreatic stent placement (PSP) for preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in high-risk cases. We performed a post hoc analysis of this RCT to explore whether rectal indomethacin can replace PSP in the prevention of PEP and to estimate the potential cost savings of such an approach.
INTRODUCTION
Preventing pancreatitis aft er endoscopic retrograde cholangiopancreatography (ERCP) remains an important clinical and research priority. Progress in the last two decades has led to substantive reductions in post-ERCP pancreatitis (PEP) rates due to more appropriate patient selection ( 1 -3 ), improved procedural techniques ( 4 -6 ) , and the adoption of prophylactic pancreatic duct (PD) stent placement (PSP) in high-risk cases.
PSP, introduced in the late 1990s, has become common clinical practice in the United States and is widely regarded as an eff ective means of preventing PEP in high-risk cases ( 7, 8 ) . While PD stent placement clearly reduces risk ( 9, 10 ) , it remains technically challenging, time consuming, and costly ( 11 -14 ) . Moreover, attempting to place a PD stent with subsequent failure actually increases the risk of PEP above baseline by inducing injury to the pancreatic orifi ce ( 15, 16 ) .
Recently, our group published a randomized controlled trial (RCT) demonstrating that rectal indomethacin, a non-steroidal anti-infl ammatory drug, reduced the risk of PEP in high-risk patients, most of whom (>80 % ) had undergone pancreatic stent placement (PSP) ( 17 ) . While this RCT found that indomethacin confers protection in addition to PSP, there are no studies examining whether indomethacin is eff ective when administered instead of PSP.
If indomethacin were to obviate the need for PSP, major clinical and cost benefi ts in ERCP practice could be realized. Th erefore, we performed a post hoc analysis of our recently reported indomethacin pharmacoprevention RCT comparing the risk-adjusted benefi ts conferred by indomethacin alone vs. prophylactic PSP alone, vs. the combination of both. We also performed a cost-benefi t analysis of these three prevention strategies.
METHODS

Patient data
Th is is a post hoc analysis of prospectively collected data obtained during a previously reported multi-center placebo-controlled trial of rectal indomethacin for preventing PEP ( 17 ) . Briefl y, aft er approval by the institutional review committees of the involved institutions, patients at elevated risk for PEP were randomized to 100 mg of rectal indomethacin or placebo suppositories administered immediately aft er ERCP. All other procedural and clinical decisions were deferred to the treating physicians. Placement of a PD stent was not mandated, however >80 % of subjects received a stent as the study enrolled patients at elevated risk for PEP.
Th e primary end point of the study was the development of PEP and the secondary end point was the severity of PEP, both defi ned according to standard consensus criteria ( 18 ) . Patient demographics, risk factors for PEP, ERCP procedural elements, and followup data were recorded on standardized data collection forms by a member of the study team who was blinded to the treatment received. All data were subsequently entered into a web-based database and managed by an independent data management service. Th e fi nal database contained information on 602 study subjects. Th e clinical and procedural characteristics collected for each subject are listed in online Supplementary Appendix A online.
Clinical comparison of prevention strategies
Eighteen percent of study subjects did not receive a prophylactic pancreatic stent as the endoscopist did not deem the case high-risk enough to merit PSP (e.g., diffi cult cannulation not requiring a precut sphincterotomy) or because placement was not technically feasible (failed pancreatic access). Fift y-one percent of subjects did not receive indomethacin as the randomization process assigned them to placebo. We, therefore, retrospectively classifi ed study subjects into four groups: (1) no prophylaxis (randomized to placebo, PSP deferred by endoscopist), (2) PD stent alone (randomized to placebo), (3) rectal indomethacin alone (randomized to indomethacin, PSP deferred by endoscopist), and (4) the combination of PD stent and indomethacin. Groups 1 and 2 comprised the control arm of the RCT while groups 3 and 4 comprised the indomethacin arm.
Comparing unadjusted PEP rates among these four groups would have yielded biased conclusions about the effi cacy of the various interventions as these study groups diff ered signifi cantly regarding their underlying risk for the primary outcome (PEP). Because the decision to place a PD stent was left to the discretion of the endoscopist, patients at higher risk for PEP were more likely to receive a stent, as they elicited more concern on the part of the endoscopist.
To correct this potential confounding, we adjusted for subjects ' underlying risk of PEP using two analytic approaches. In the fi rst analysis, we included patient ' s ' PEP risk score ' as a covariate in a logistic regression model with PEP (dichotomous) as the dependent variable and PD stent placement and indomethacin treatment as predictor variables. Th e risk score was calculated for each subject by assigning one point for each major RCT inclusion criterion and 0.5 points for each minor RCT inclusion criterion ( 17 ) . Th is resulted in a continuous risk score ranging from 0.5 to 5.5. For example, a patient included in our study for a clinical suspicion of sphincter of Oddi dysfunction (major inclusion criterion) who experienced pancreatic acinarization (minor inclusion criterion) and underwent a pancreatic sphincterotomy (major inclusion criterion) had a risk score of 2.5. Th e criteria used to calculate the risk score are listed in Table 1 .
While an increasing risk score did predict a higher likelihood of PEP in our clinical study, this relationship did not appear linear, likely due to the synergistic nature of PEP risk factors ( 19 ) ( Figure 1 ). Moreover, every major inclusion criterion contributed equally to our risk score, even though certain inclusion criteria are known to confer more risk for PEP than others. Th us, the PEP risk score may not have resulted in an adequate adjustment, and we, therefore, also attempted to control for risk using a second approach. In this second analysis, we calculated a propensity score for every subject ' s probability of receiving a pancreatic stent. Th is propensity score predicts a subject ' s conditional probability of receiving a PD stent based on all of the other observed characteristics of that subject, including the criteria used to generate the risk score and other factors such as age, gender, biliary interventions, study site, and trainee involvement in the ERCP. As patients at higher risk for PEP were more likely to receive a stent, we included the propensity score as a surrogate marker for PEP risk (along with PD stent placement and indomethacin treatment) in a second logistic regression model. 
Cost-benefi t analysis
Utilizing the analyses outlined above, published literature, and publicly available cost data, we estimated the cumulative costs of care associated with three PEP prevention strategies: (1) rectal indomethacin alone, (2) PSP alone, and (3) PSP plus indomethacin from the perspective of a 3rd party payer. As indomethacin monotherapy was less costly and more eff ective than either PSPbased strategy (see results below), we did not perform a typical cost-eff ectiveness analysis (which presumes that one strategy is both more eff ective and more costly than another). Rather, we performed a cost-benefi t analysis, with the primary goal of projecting the potential cost savings associated with indomethacin alone prophylaxis in individuals undergoing high-risk ERCP.
Th e clinical probabilities and assumptions used in this analysis are listed in Table 2 . Th e probabilities of developing PEP associated with each of the 3 strategies were calculated in the fi rst portion of this study using the methodology described above. We assumed that all ERCPs were performed by expert endoscopists who would be frequently successful in PD stent placement ( 12 -14 ) , and that attempted but unsuccessful placement of a PD stent would result in an elevated risk of PEP ( 15, 16 ) . We also assumed that an abdominal radiograph would be obtained in all patients undergoing PSP to document spontaneous stent passage, and endoscopic retrieval would be performed in those with retained stents ( 14 -16 ) . We assumed that no complications occurred during follow-up upper endoscopy (biasing our results in favor of PSP-based strategies).
Cost estimates for the endoscopic procedures and abdominal radiographs were obtained from 2012 regional Medicare reimbursement data for southeast Michigan ( 20 ) . Th e cost of hospitalization for PEP was obtained from the Healthcare Cost and Utilization Project through the Agency for Healthcare Research and Quality ( 21 ) . Th e cost of generic indomethacin suppositories was obtained from a national vendor (G & W Laboratories, South Plainwell, NJ). Costs estimates are summarized in Table 3 .
Sensitivity analysis was used to identify variables that had important eff ects on cost. One-way sensitivity analyses were performed on each variable in the model. Two-way sensitivity analyses were performed using variables identifi ed in one-way analyses. Probabilistic sensitivity analysis (2nd order Monte Carlo analysis) was also performed, where 13 variables were simultaneously varied over their sensitivity analysis ranges according to specifi ed probability distributions (100,000 Monte Carlo trials) ( Tables 2 and 3 ). Beta and gamma distributions were assumed for proportions and costs, respectively ( 22 ) . For each distribution, we assumed that the mean was equal to the point estimate and that the s.d. was equal to the sensitivity analysis range / (2 × 1.96). Results were used to calculate 95 % confi dence intervals around base-case cost estimates. We also evaluated cost-eff ectiveness and generated acceptability curves for each strategy using net benefi ts calculations. As our model focused on a discrete event (ERCP and its immediate complications), discounting of costs and life-years was not performed .
Statistical analysis
All statistical analyses were performed using the STATA 12 statistical package (StataCorp LP, College Station, TX). Propensity score calculation was conducted using the psmatch2 command ( 23 ) . Predicted marginal probabilities for PEP aft er logistic regression 
RESULTS
Risk of PEP
Th e unadjusted PEP rates in the four groups are listed in Table 4 . Th e group of subjects who received no prophylaxis ( n = 58) had a PEP rate of 20.7 % . Th ose who received a pancreatic stent alone ( n = 249) had a PEP rate of 16.1 % . Th ose who received both indomethacin and a PD stent ( n = 247) had a PEP rate of 9.7 % , and the group who received indomethacin alone ( n = 48) had a PEP rate of 6.3 % .
Patients who received a PD stent were indeed at higher risk for PEP, evidenced by a higher mean risk score (2.50 vs. 1.84, P < 0.001) and a higher likelihood of having a clinical suspicion of sphincter of Oddi dysfunction (87 vs. 59 % ) or having undergone a pancreatic sphincterotomy (68 vs. 6 % ).
Risk adjustment using PEP risk score
Aft er adjusting for risk by including subject ' s risk score in the multivariable logistic regression model, the rates of PEP in the four groups were as follows ( Table 4 ): 25.7 % . for subjects receiving no prophylaxis, 15.3 % for subjects receiving stent alone, 9.4 % for subjects receiving the combination of indomethacin and PSP, and 7.8 % for those who received indomethacin alone.
Risk adjustment using propensity score to receive a pancreatic stent
Aft er adjusting PEP rates according to subject ' s propensity score to receive a pancreatic stent in the multivariable logistic regression model, the rates of PEP in the four groups were as follows ( Table 4 ): 23.1 % for subjects receiving no prophylaxis, 15.7 % for subjects receiving stent alone, 9.5 % for subjects receiving the combination of indomethacin and PSP, and 7.1 % for those receiving indomethacin alone.
Cost-benefi t analysis
In our economic analysis, the base-case cost of care for one high-risk ERCP patient who receives indomethacin alone is $ 3,042.70 compared with $ 3,834.54 for the combination of indomethacin and PSP, and $ 4,515.04 for PSP alone. In sensitivity analysis, the variables with the largest impact on total cost were the cost of ERCP and the cost of PEP. However, no single variable resulted in indomethacin monoprevention becoming more costly than either PSP-based strategy. Monte Carlo analysis revealed that indomethacin mono-prevention results in a mean per-patient savings of $ 793.80 (95 % confi dence interval: − 112.60 -1619.00) over the combination of indomethacin and PSP, and $ 1,472.40 (95 % confi dence interval: 491.00 -2804.10) over PSP alone. In ~ 4 % of trials, the combination of indomethacin and PSP was less costly than indomethacin alone. Using net benefi ts calculations, indomethacin alone was the most cost-eff ective strategy in ~ 96 % of trials regardless of willingness-to-pay, up to a willingness-to-pay threshold of $ 100,000 per life-year gained ( Figure 2 ). Assuming that 20 % (100,000) of the 500,000 ERCPs that occur annually in the United States are high-risk cases, then the indomethacin alone strategy would save approximately $ 150 million per year compared with the PSP alone strategy, and $ 85 million per year compared with the indomethacin plus PSP strategy (assuming base-case values). In addition to the potential reduction in PEP, an indomethacin alone strategy would avoid the phenomenon of attempted but failed PSP, which is associated with a high rate of PEP by activating aforementioned pathogenic factors but providing no ductal decompression. It would also avoid the 4 % of cases that result in signifi cant non-pancreatitis complications induced by PSP, such as stent migration and duct perforation ( 10 ) , as well as the rare complications that occur during follow-up upper endoscopy to remove retained stents.
Economically, this study demonstrated that indomethacin mono-prevention would save approximately $ 150 million annually in the United States compared with PSP alone, and $ 85 million annually compared with combination therapy. Moreover, as PSP requires ~ 10 min to perform ( 14 ) , indomethacin mono-prevention would save ~ 1 million procedural minutes (or 16,666 procedure hours) annually, benefi cial to patients and endoscopy units alike by allowing unit and physician manpower for delivery of other endoscopic services.
Despite these proposed clinical and cost benefi ts, this analysis is intended to be hypothesis-generating, and, therefore, the results of this study should not change clinical practice at this time. Th is post hoc observational study does not produce the same quality of evidence as our RCT, which supports the use of indomethacin in addition to PSP in high-risk cases ( 17 ) . Moreover, the results of this study must be interpreted in the context of several important limitations. First, underlying subject risk was adjusted by accounting for variations in the observed characteristics of study participants. Unobserved and unrecorded patient and procedural characteristics, however, are also likely to contribute to subject risk and may not have been accounted for in our risk adjustment analyses.
Second, the cost analysis was based on the adjusted PEP pancreatitis rates seen in our indomethacin pharmacoprevention RCT and may not refl ect the frequency of this complication in other institutions or regions. Further, the calculations were based on local Medicare reimbursement rates, which vary regionally, and Medicare reimbursement for stent placement may be lower than stated when multiple interventions are performed during the same ERCP. While these factors likely limit the generalizability of the economic analysis results, the cost savings associated with an indomethacin alone strategy remain substantial when clinical probabilities and costs were varied broadly in the sensitivity analysis. Despite these limitations, the hypothesis generated by the fi ndings of this study is of major potential impact and merits further investigation.
In summary, this hypothesis-generating study suggests that prophylactic rectal indomethacin may eliminate the need for PSP in patients undergoing high-risk ERCP. A prevention strategy involving indomethacin alone could improve clinical outcomes and substantially reduce healthcare costs. Th erefore, a RCT comparing rectal indomethacin alone vs. indomethacin plus PSP appears justifi ed.
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DISCUSSION
Th is post hoc analysis of a prospective RCT found that, aft er adjusting for diff erences in underlying risk using two diff erent approaches, patients who received prophylactic rectal indomethacin alone appeared to have a lower risk of PEP than those who received a prophylactic pancreatic stent alone or the combination of both preventive interventions. Th e associated economic analysis suggests that a prevention strategy of indomethacin alone could substantially reduce healthcare costs associated with high-risk ERCP.
Prophylactic PSP is thought to reduce the risk of PEP by relieving pancreatic ductal hypertension that develops because of procedure-induced edema and stenosis of the pancreatic orifi ce ( 12, 13, 24 ) . PD stent placement, however, is not completely eff ective as orifi ce edema is only one of several relevant pathophysiologic mechanisms in PEP. Other factors, such as chemical, allergic, enzymatic, and infectious injury are also though to contribute ( 25 ) , and may be induced or potentiated by the process of placing a PD stent. Indeed, indomethacin alone may be more eff ective than any strategy involving PSP as it avoids manipulation of the pancreatic orifi ce and instrumentation of the PD. 
Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Rectal indomethacin administration is effective in addition to pancreatic stent placement for preventing PEP in high-risk patients.
3 There are no studies examining whether rectal indomethacin is effective when administered instead of PSP.
WHAT IS NEW HERE
3 After adjusting for risk, rectal indomethacin alone appeared to be more effective for preventing PEP than no prophylaxis, PSP alone, and the combination of indomethacin and PSP.
3 A prevention strategy employing rectal indomethacin alone could save approximately $ 150 million annually in the United States compared with a strategy of PSP alone, and $ 85 million compared with a strategy of indomethacin and PSP.
3 A randomized controlled trial comparing rectal indomethacin alone vs. indomethacin plus pancreatic stent placement appears justifi ed.
